Soon after they were first described in 1990, aptamers were largely recognized as a new
class of biological ligands that can rival antibodies in various analytical, diagnostic, and …

Surface functionalization of liposomes can play a key role in overcoming the current
limitations of nanocarriers to treat solid tumors, ie, biological barriers and physiological …

Functional nucleic acid (NA)-based drugs have a broad range of applications since they
allow the alteration and control of gene/protein expression patterns in cells. In principle …

Using nanoparticles to carry and delivery anticancer drugs holds much promise in cancer
therapy, but nanoparticles per se are lacking specificity. Active targeting, that is, using …

RNA interference (RNAi) is considered a highly specific approach for gene silencing and
holds tremendous potential for treatment of various pathologic conditions such as …

Aptamers with high affinity and specificity for certain targets have rapidly become a novel
class of targeted ligands applicated in drug delivery. Based on the excellent characteristics …

Breast carcinomas repeat their number and grow exponentially making it extremely frequent
malignancy among women. Approximately, 70–80% of early diagnosed or non-metastatic …

Aptamers are versatile nucleic acid-based macromolecules characterized by their high
affinity and specificity to a specific target. Taking advantage of such binding properties …

In the last decade, investigators have put significant efforts to develop several diagnostic
and therapeutic strategies against cancer. Many novel nanoplatforms, including lipidic …

Nanoparticles (NPs) are promising drug delivery systems (DDS) for identifying and treating
cancer. Active targeting NPs can be generated by conjugation with ligands that bind …